Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of MK-6194 in Adult Participants with Non-segmental Vitiligo
jRCT2031230622Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of PT101 in Vitiligo (3 arms), sponsored by Merck & Co. Primary endpoints: Change from Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24, Number of Participants Who Experience an Adverse Event (AE) and 1 more. Started Mar 2024; status: completed.
02
Drugs
PT101
03
Conditions
Vitiligo
Beyond the preview
Go deeper on jRCT2031230622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230622.